title: Efficacy of ibandronate: a long term confirmation.
abstract: Data deriving from randomized clinical trials, observational studies and meta-analyses, including treatment regimens unlicensed for use in clinical practice, clearly support that 150 mg once-monthly oral and 3 mg quarterly i.v. doses of ibandronate are associated with efficacy, safety and tolerability; notably both these marketed regimens, which largely correspond to ACE ≥10.8 mg, may in addition provide a significant efficacy on non-vertebral and clinical fracture (Fx) efficacy. The MOBILE and the DIVA LTE studies confirmed a sustained efficacy of monthly oral and quarterly i.v. regimens respectively, over 5 years. Furthermore, improved adherence rates with monthly ibandronate, deriving from studies evaluating large prescription databases, promise to enhance fracture protection and decrease the social and economic burden of postmenopausal osteoporosis.
authors.affiliation: Professor of Rheumatology, Rheumatology Unit, Department of Internal Medicine, University of Pisa.
authors.forename: Ombretta
authors.initials: O
authors.lastname: Di Munno
authors.forename: Andrea
authors.initials: A
authors.lastname: Delle Sedie